Juhe Biotechnology is a technology company.
Juhe Biotechnology has raised $14.0M across 1 funding round.
Juhe Biotechnology has raised $14.0M in total across 1 funding round.
Juhe Biotechnology has raised $14.0M in total across 1 funding round.
Juhe Biotechnology's investors include Harmonix Fund, LongeVC, Prosperity7 Ventures, Qiming Venture Partners.
Juhe Biotechnology is a technology-driven company primarily focused on developing early detection tools for gynecological cancers through advanced DNA methylation analysis to identify critical biomarkers[3][4][6]. It serves healthcare providers and patients by addressing the urgent need for early and accurate cancer diagnostics, which can significantly improve treatment outcomes. Additionally, there is a related entity, Hangzhou Juhe Biotech, which operates as a professional food additive manufacturer integrating R&D, production, and sales, serving over 10 listed companies and customers across 30 provinces in China with a diverse product system and a strong innovation portfolio[2]. The biotechnology arm shows growth momentum by leveraging cutting-edge molecular diagnostic technologies, while the food additive business has demonstrated consistent revenue growth and national recognition as a high-tech enterprise[2].
Juhe Biotechnology’s founding details vary slightly by location, but the core biotech company focusing on cancer diagnostics emerged with a mission to innovate in early disease detection using molecular biology techniques[3][4]. Hangzhou Juhe Biotech was founded in 2012 by LIU Runyu, who emphasized a customer-centric business philosophy rooted in consensus, responsibility, and shared duties. The company developed through close collaboration with Zhejiang University and China National Research Institute of Food and Fermentation Industries, gaining early traction by serving well-known brands and securing patents and software copyrights[2]. This blend of academic partnership and market-driven innovation has been pivotal in its growth.
Juhe Biotechnology rides the global trend of precision medicine and molecular diagnostics, where early detection of diseases like cancer is critical for improving patient outcomes. The timing is favorable due to increasing healthcare demands, advances in genomics, and growing awareness of women's health issues. Market forces such as rising cancer incidence and government support for biotech innovation in China further bolster its position. By providing advanced diagnostic tools, Juhe influences the broader healthcare ecosystem by enabling earlier interventions and potentially reducing treatment costs and mortality rates[3][4].
Looking ahead, Juhe Biotechnology is poised to expand its diagnostic portfolio and deepen its clinical adoption, potentially entering broader markets beyond gynecological cancers. Trends in AI integration, personalized medicine, and non-invasive diagnostics will likely shape its journey. Its influence may grow as it contributes to shifting healthcare paradigms toward prevention and early intervention. For Hangzhou Juhe Biotech, continued innovation in food additives aligned with health trends and sustainability could drive further growth. Both entities exemplify how biotechnology companies can leverage technology and partnerships to address critical health and industry needs, maintaining momentum in a competitive and evolving landscape[2][3][4].
Juhe Biotechnology has raised $14.0M across 1 funding round. Most recently, it raised $14.0M Series B in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2023 | $14.0M Series B | Harmonix Fund, LongeVC, Prosperity7 Ventures, Qiming Venture Partners |